Many significant brain disorders, such as LVO, cause dangerous blood flow disruptions.
This analysis is non-invasive, can be performed in the physician’s office, and helps the physician diagnose brain disorders, potentially without the need for additional, more invasive tests. The Lucid System uses TCD ultrasound to assess the brain’s blood vessels from outside the body. Advanced technologies like the Lucid System can dramatically improve healthcare management for patients who suffer from stroke each year by providing a device to help physicians triage these patients quickly and accurately. The Lucid System studied in the EXPEDITE program is comprised of two key components: an FDA cleared transcranial ultrasound system, and an IRB-approved investigational automation technology designed to simplify data collection for healthcare practitioners.
“This technology has the potential to dramatically influence how we measure and track patients with serious brain injuries all across the world.” “With the Lucid System, we can look inside the brain at blood flow patterns in real time and identify physiological changes associated with brain disorders including stroke,” said Robert Hamilton, Ph.D., co-founder and chief scientific officer of Neural Analytics. The first phase of the EXPEDITE program enrolled patients at Erlanger Southeast Regional Stroke Center in Chattanooga, Tenn., and Baptist Stroke & Cerebrovascular Center in Jacksonville, Fla., to examine the feasibility of Neural Analytics’ Lucid TCD Ultrasound System in the measurement of cerebral blood flow in patients with LVO. Devlin presented the data demonstrating that Neural Analytics’ Lucid System is capable of measuring and displaying LVO with 91 percent sensitivity and 85 percent specificity as compared to the current standard of care imaging in persons suspected of having a stroke. “We are honored to be the first site in the world to evaluate this technology with the goal of improving our stroke patient outcomes.”ĭr.
#TRANSCRANIAL DOPPLER MACHINES PORTABLE#
“The research results of the EXPEDITE program demonstrate that Neural Analytics’ portable diagnostic platform, the Lucid System, has the potential to influence how fast we detect stroke, triage and treat patients,” said Thomas Devlin, M.D., medical director of Erlanger’s Southeast Regional Stroke Center, 2017 SVIN Stroke Workshop chair and principal investigator of the study. The data was presented at the 10th annual Society of Vascular and Interventional Neurology (SVIN) meeting in Boston, MA. Neural Analytics Inc., a medical device company developing and commercializing technology to measure, diagnose, and track brain health, today announced the results from the first phase of the EXPEDITE (Expedite a NeXt Generation PortablE Diagnostic Platform for Determination and Immediate Triage of Emergency Large Vessel Stroke) program, which (under IRB approved investigation) demonstrates the company’s advanced Transcranial Doppler (TCD) technology platform was accurate with over 94 percent area under the curve (AUC) for early measurement of acute ischemic stroke (AIS) due to large vessel occlusion (LVO).
0 kommentar(er)
